ポスト

AbbVie announced preliminary positive results from phase 3 SELECT-GCA study showing remission in 46% of #GCA pts Rx w/ upadacitinib for 52wks (vs 29% PBO); RCT included a 26-wk steroid taper regimen https://t.co/DIstJ4hazo

メニューを開く

Dr. John Cush@RheumNow

人気ポスト

もっと見る
Yahoo!リアルタイム検索アプリ